Relationship between abnormal activation of HGF/c-Met signaling pathway and EGFR-TKI acquired resistance in non-small cell lung cancer
- VernacularTitle:非小细胞肺癌中 HGF/c-Met 信号通路与 EGFR-TKI 获得性耐药的关系
- Author:
Lin NIE
;
Yuqing XU
- Publication Type:Journal Article
- Keywords:
Proto-oncogene protein c-met;
Hepatocyte growth factor;
Carcinoma,non-small-cell lung
- From:
Journal of International Oncology
2016;43(9):703-705
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy such as the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)has made huge progress in treatment of non-small cell lung cancer (NSCLC).However,the emergence of acquired drug resistance is an inevitable result of the targeted therapy.The hepatocyte growth fac-tor/c-mesenchymal-epithelial transition factor (HGF /c-Met)signaling pathway participates in cell formation, migration,angiogenesis and other important cellular processes of multiple tumors.The abnormal activation of this signaling pathway plays the pivotal role in the acquired resistance to EGFR-TKI.Recently,some clinic tri-als prove that HGF /c-Met inhibitors can make clinical benefit of some NSCLC patients with acquired drug re-sistance of EGFR-TKI.
